Journal of Gastroenterology and Digestive Diseases

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (629)348-3199

Short Communication - Journal of Gastroenterology and Digestive Diseases (2023) Volume 8, Issue 6

Updates in screening and early detection of gastrointestinal cancers: A comprehensive overview.

Alizamen Mirzaei*

Department of Medical Biotechnology, Shahrekord University of Medical Sciences, Shahrekord, Iran

*Corresponding Author:
Alizamen Mirzaei
Department of Medical Biotechnology
Shahrekord University of Medical Sciences, Shahrekord, Iran
E-mail: mirzae.a@skums.ac.ir

Received: 17-Oct-2023, Manuscript No. JGDD-23-120824; Editor assigned: 19-Oct-2023, Pre QC No. JGDD-23-120824 (PQ); Reviewed: 02-Nov-2023, QC No. JGDD-23-120824; Revised: 06-Nov-2023, Manuscript No. JGDD-23-120824 (R); Published: 13- Nov-2023, DOI: 10.35841/ jgdd -8.6.179

Citation: Mirzaei A. Updates in screening and early detection of gastrointestinal cancers: A comprehensive overview. J Gastroenterol Dig Dis.2023;8(6):179

Visit for more related articles at Journal of Gastroenterology and Digestive Diseases

Introduction

Gastrointestinal (GI) cancers pose a significant health challenge globally, with their incidence steadily rising. Early detection plays a crucial role in improving outcomes and reducing mortality rates associated with these malignancies. Recent advancements in screening technologies and strategies have paved the way for more effective and accessible methods for early detection. Colorectal cancer (CRC) remains a leading cause of cancer-related morbidity and mortality. Colonoscopy, a gold standard for CRC screening, has seen technological enhancements aimed at improving its efficacy and patient experience. Virtual colonoscopy, or computed tomography colonography, is gaining popularity as a noninvasive alternative. It utilizes advanced imaging techniques to generate detailed 3D images of the colon, offering a less invasive option for individuals averse to traditional colonoscopy [1, 2].

Furthermore, fecal immunochemical tests (FIT) and stool DNA tests have emerged as convenient at-home screening options. FIT detects blood in the stool, while stool DNA tests can identify specific genetic mutations associated with CRC. These non-invasive tests provide an accessible and userfriendly alternative for individuals who may be hesitant to undergo traditional screening methods. Esophageal cancer, particularly adenocarcinoma and squamous cell carcinoma, has a high mortality rate due to late-stage diagnoses. Advances in endoscopic technology have enabled the development of innovative screening techniques. Narrow Band Imaging (NBI), for instance, enhances the visibility of subtle mucosal changes, aiding in the early detection of esophageal lesions. Endoscopic ultrasound (EUS) has also evolved, allowing for more accurate staging and localization of tumors within the esophagus [3, 4].

The development of minimally invasive techniques, such as capsule endoscopy, offers a less invasive approach to evaluating the esophagus for abnormalities. This ingestible capsule equipped with a tiny camera captures images as it travels through the digestive tract, providing valuable diagnostic information without the need for traditional endoscopy. Stomach or gastric cancer often presents late in its course, making early detection challenging. Recent advances in imaging technologies, such as positron emission tomography (PET) and endoscopic ultrasound, contribute to more accurate staging and localization of gastric tumors. These tools help guide treatment decisions and improve overall patient outcomes [5, 6].

Serum biomarkers, such as carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9), play a role in the surveillance and early detection of gastric cancer. Regular monitoring of these markers, especially in high-risk populations, can aid in identifying potential cases at an earlier, more treatable stage. Hepatocellular carcinoma (HCC) is the most common primary liver cancer, often associated with chronic liver diseases such as cirrhosis. Routine surveillance of high-risk individuals, such as those with chronic hepatitis B or C infections, is crucial for early detection [7, 8].

Ultrasonography, alpha-fetoprotein (AFP) testing, and MRI are among the tools employed in the surveillance and early diagnosis of liver cancer. The advent of liquid biopsy, a noninvasive method for detecting circulating tumor DNA, is showing promise in the early detection of liver cancer. This approach allows for the identification of genetic mutations associated with HCC through a simple blood test, offering a convenient and potentially more sensitive screening method [9, 10].

Conclusion

The landscape of gastrointestinal cancer screening is rapidly evolving, with continuous advancements in technology and a growing emphasis on accessibility. From innovative endoscopic techniques to non-invasive screening options, the field is making significant strides in improving early detection rates. As these technologies become more widely available, there is hope that the burden of gastrointestinal cancers on global health can be alleviated through earlier diagnoses and more effective interventions.

References

  1. Cesarone MR, Laurora G, De Sanctis MT, et al. The microcirculatory activity of Centella asiatica in venous insufficiency. A double-blind study. Minerva Cardioangiol. 1994;42(6):299-304.

    2. Indexed at, Google Scholar

  2. Chiaretti M, Fegatelli DA, Ceccarelli G, et al. Comparison of Flavonoids and Centella asiatica for the treatment of chronic anal fissure. A randomized clinical trial. Ann Ital Di Chir. 2018;89:330-6.

    3. Indexed at, Google Scholar

  3. Paocharoen V. The efficacy and side effects of oral Centella asiatica extract for wound healing promotion in diabetic wound patients. J Med Assoc Thai. 2010;93(Suppl 7):S166-70.

    4. Indexed at, Google Scholar

  4. Belcaro GV, Grimaldi R, Guidi G. Improvement of capillary permeability in patients with venous hypertension after treatment with TTFCA. Angiology. 1990;41(7):533-40.

    5. Indexed at, Google Scholar, Cross Ref

  5. Montecchio GP, Samaden A, Carbone S, et al. Centella Asiatica Triterpenic Fraction (CATTF) reduces the number of circulating endothelial cells in subjects with post phlebitic syndrome. Haematologica. 1991;76(3):256-9.

    6. Indexed at, Google Scholar

  6. Cataldi A, Gasbarro V, Viaggi R, et al. Effectiveness of the combination of alpha tocopherol, rutin, melilotus, and centella asiatica in the treatment of patients with chronic venous insufficiency. Minerva Cardioangiol. 2001;49(2):159-63.

    7. Indexed at, Google Scholar

  7. Sharp GC, Irvin WS, Tan EM, et al. Mixed connective tissue disease-an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med. 1972;52(2):148-59.

    8. Indexed at, Google Scholar, Cross Ref

  8. Marie I, Dominique S, Levesque H, et al. Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Care & Research: Official Journal of the American College of Rheumatology. 2001;45(4):346-54.

    9. Indexed at, Google Scholar, Cross Ref

  9. Troshinsky MB, Kane GC, Varga J, et al. Pulmonary function and gastroesophageal reflux in systemic sclerosis. Ann Intern Med. 1994;121(1):6-10.

    10. Google Scholar

  10. Smolen JS, Steiner G. Mixed connective tissue disease: to be or not to be?. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 1998;41(5):768-77.

    11. Google Scholar

Get the App